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Accomplishments
• Measured mobile source air toxics (MSATs) from European Saab Biopower vehicle that is optimized for performance with E85 fuel to provide information on the health impact of ethanol fuel introduction.
-E85 increases cold-start ethanol emissions to levels of 48 mg/mile on the Federal Test Procedure (FTP) driving cycle.
-E85 reduces gasoline-derived MSAT emissions by a factor of 10 as compared with gasoline fuel over the FTP and US06 driving cycles.
• Characterized mobile source air toxics from high efficiency clean combustion (HECC) on a diesel engine to determine any health impacts of advanced diesel combustion modes.
-Formaldehyde emissions from HECC were a factor of two higher than the traditional diesel combustion emissions.
-Acetaldehyde and acrolein emissions were also observed to increase significantly during HECC operation.
Future Directions
• Evaluate the impact of butanol fuel addition to ethanol-gasoline fuel mixtures on emissions.
• Determine the efficiency of catalytic aftertreatment for reduction of MSATs from HECC diesel operation.
Introduction
Scientists and engineers at national laboratories, universities, and industrial companies are developing energy efficient technologies for transportation, and the U.S. Department of Energy (DOE) is actively involved in this innovative research. However, care must be taken to insure that any new technology developed for transportation must not adversely directly impact human health or impact the health of the environment, which subsequently may impact human health. To address this need, DOE sponsors research studies on the potential health impacts of advanced technologies for transportation including advanced fuels, combustion techniques, and emissions controls (also known as "aftertreatment" or, more commonly, "catalytic converters"). DOE sponsored health impact research activities at Oak Ridge National Laboratory (ORNL) are presented in this report.
ORNL conducts research on advanced fuel, combustion and emissions control technologies at the National Transportation Research Center (a joint ORNL and University of Tennessee research center) in Knoxville, TN. As the research is being conducted on engine and chassis dynamometers, specific studies of the potential health impacts of the technologies are conducted by the ORNL team for DOE's health impacts program. Results from two ORNL studies in FY 2007 are presented here. Both studies focused on measuring MSATs from advanced technologies; the technologies were (1) an ethanol fuel optimized vehicle and (2) an advanced diesel combustion technique that results in simultaneous reduction of NOx and particulate emissions called HECC.
emissions were sampled and analyzed with a variety of and load with the engine operating in HECC mode. The techniques including Fourier transform infrared (FTIR) MSAT emissions from both the traditional and advanced and gas and liquid chromatography via collection with HECC combustion modes were measured with FTIR 2,4-dinitorophenylhydorazine (DNPH) cartridges. The and gas and liquid chromatography via collection with measurements were cycle averages for the FTP and US06 DNPH cartridges. driving cycles; a photo of the vehicle on the chassis dynamometer is shown in Figure 1 . In addition to MSAT results emissions, ethanol, an unregulated species, was quantified.
MSATs from E85 Fueled Vehicle MSATs from HECC Diesel Mode
Ethanol emissions with E85 fuel operation were A Mercedes 1.7-liter 4-cylinder diesel engine was found only during the FTP driving cycle, but aldehyde operated at 1,500 rpm and 2.6 brake mean effective emissions, typically associated with alcohol motor fuels, pressure (BMEP) on an engine dynamometer under were higher than with gasoline operation, as shown in production calibration conditions that are typical of Figure 3 . All of the FTP emissions essentially occurred traditional diesel combustion. The engine is shown in in Bag 1 of the driving cycle, which indicates that the Figure 2 . The load and speed chosen are representative ethanol emissions were primarily due to cold operating of a universal moderate load condition for a light-duty conditions. Qualitative observation of the FTIR data vehicle. The engine was also operated at the same speed indicated that the first thirty seconds of the Bag 1 portion was the source of both the ethanol and aldehyde emissions. The very low levels of aldehyde emissions during the US06 indicate that they are primarily associated with cold operation.
Although an increase was observed in ethanol emissions from E85 for cold conditions, E85 fuel demonstrated beneficial reduction of some MSAT species. Figure 4 shows select MSAT species emissions that are derived from gasoline fuel. The summation of these MSAT emissions decreased substantially for the E85 fuel relative to gasoline. The MSAT reduction occurred for both FTP and US06 driving cycles. Note that the US06 gasoline fuel results show higher levels of MSATs than the FTP gasoline fuel data due to the more aggressive driving cycle of the US06 test which results in more enrichment operation of the engine; enrichment
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Emissions (mg/hr)
Diesel operation with the advanced HECC technique leads to a simultaneous reduction in NOx and particulate emissions without sacrificing fuel efficiency. At the 1,500 rpm, 2.6 BMEP operating condition used in this study, HECC operation resulted in a 90% reduction in NOx and a 70% reduction in smoke as compared with traditional diesel combustion. However, MSAT 600 400 emissions for HECC were greater than with traditional diesel combustion. Formaldehyde Acetaldehyde Acrolein baseline (traditional combustion) conditions. Increases in the concentration of these species were even more significant due to the fact that lower exhaust flow results from HECC. Since emission regulations are mass-based as opposed to concentration-based, the emissions data here is reported as mass. The formaldehyde emissions were the highest and were almost double for HECC vs. the baseline. Although acetaldehyde and acrolein emissions were lower than formaldehyde, the increase in acetaldehyde and acrolein emissions relative to the baseline case were more dramatic. All the data reported here was obtained without emission control in the engine exhaust. Catalytic aftertreatment may be able to substantially reduce the increased MSAT emissions measured and will be the focus of future work.
Hexane Ethylbenzene
Xylene Benzene
1-Pentene Toluene
conclusions
• E85 Fueled Saab Biopower Vehicle:
-E85 fuel decreases the amount of gasolinederived MSATs by a factor of approximately 10 in comparison to gasoline fuel during FTP and US06 driving cycles.
-Ethanol emissions increase dramatically for E85 in comparison to gasoline for the FTP driving cycle due to cold start emissions, but no increase in ethanol emissions were observed for the higher temperature US06 driving cycle.
• High Efficiency Clean Combustion:
-In comparison to traditional diesel combustion, HECC operation results in lower NOx and particulate matter emissions; however, MSAT emissions from HECC were higher.
Formaldehyde emissions from HECC were almost a factor of two greater than from 
E85 Gasoline
Emissions (mg/mi) traditional combustion. 
Objective
The objective of this project is to quantify the role of engine lubricating oil on particulate matter (PM) emissions from in-use motor vehicles fueled with gasoline, 10% ethanol (E10), diesel, biodiesel, and compressed natural gas (CNG) while operating on fresh and used crankcase lubricants. • Obtained funding from the Coordinating Research Council (sponsored by the automotive and petroleum industries) for program support.
• Obtained support from the American Chemistry Council Petroleum Additives Product Approval Protocol Task Group to provide new and aged engine lubricating oils for all vehicles that will be tested in the program.
• Increased scope of project to include medium-duty vehicles and E10 and biodiesel fuel testing as part of the overall project.
• Began testing of first vehicle in program in May 2007.
Future Directions
A variety of light-, medium-, and heavy-duty (LD, MD, HD) vehicles will be tested over different driving test cycles at room temperature (72°F) and cold temperature (20°F) on chassis dynamometers. The test matrix depicting the vehicles and test conditions is shown in Table 1 . 
The engine lubricating oil used in the program is labeled with deuterated hexatriacontane (C 36 D 74 ). This tracer, along with other naturally-occurring compounds found in lubricating oil, such as hopanes and steranes, will be used to quantify the relative contributions of PM formed from the fuels and the lubricants used in the vehicles that will be tested.
Normal and high-emitting vehicles representing gasoline, diesel, and CNG-powered vehicles will be tested. Lubricants used in each technology will be representative of those currently on the market, with both new and aged lubricants being tested in the program. The fuels used in the vehicles will be gasoline containing no ethanol, E10, CARB diesel, biodiesel, and CNG. Room temperature and cold temperature testing will be performed on all of the light-and medium-duty
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vehicles. Cold temperature testing will not be conducted on the heavy-duty vehicles due to funding limitations.
The data collected throughout the study will be chemically analyzed with detailed speciation to quantify the relative importance of the fuel and lubricant to PM emissions from these vehicles under the variety of testing conditions specified in the study design.
Recent air quality studies conducted in Denver, Phoenix, Washington D.C., and Office of FreedomCAR and Vehicle Technologies' (OFCVT) Gasoline/Diesel PM Split Study in Los Angeles have shown that PM from gasoline engines is a more significant contributor to ambient air quality than PM from diesel engines [1, 2] . For example, data collected in Washington, D.C., over a ten-year period suggest that PM from gasoline exhaust is ten times more important to the emission inventory than diesel exhaust, as shown in Figure 1 [3] .
OFCVT's Comparative Toxicity Studies have also shown that the toxicity from gasoline exhaust on a perunit-mass basis is at least as toxic as that from diesel exhaust, and that high emitters' toxicity is even greater than that from normal emitters [4] .
Because PM from both gasoline and diesel exhaust is so important to human health and ambient air quality, it is important to understand its source -whether it derives from the fuel, the lubricant, or both, and to understand the engine operating conditions that are responsible for PM emissions. That is the objective of the CLOSE Program. 
Washington
58%
Approach
The CLOSE Program will conduct extensive chemical and physical characterizations of PM emissions from vehicles fueled with gasoline, E10, diesel, biodiesel, and natural gas while operating on fresh and used crankcase lubricants in an effort to improve our current understanding of the impact of crankcase lubricant formulations on vehicle PM emissions. In-use light-and heavy-duty vehicles are being recruited, including both normal and high-PM emitters, and operated on chassis dynamometers at room temperature (72°F nominal) and 20°F. Gaseous (total hydrocarbons [THC], nonmethane hydrocarbons [NMHC], carbon monoxide [CO], nitrogen oxides [NOx]) and real-time particle emissions are being measured, and PM and semivolatile organic compound (SVOC) samples are being collected for subsequent chemical analyses. Physical PM measurements will be conducted to obtain data on particle size, which will be investigated over the various driving conditions carried out on the dynamometers.
results
At the time of this report, vehicle testing has begun on the light-duty normal emitter, which is a 2006 Chevy Impala having 37,000 miles on the odometer. Figure 2 shows the vehicle on the dynamometer, and Figure 3 shows the sampling ports and equipment used in the sampling tunnel. 
Approach
• Use animal and cell tests to characterize and quantify adverse health effects.
• Adapt, optimize, and validate biological test systems for emissions testing.
• Test whole and fractionated emissions from engines operated in the laboratory and vehicles operated elsewhere.
• Conduct detailed physical-chemical analysis of emissions and samples.
• Use physical-chemical fractionation and exposures to specific compounds to identify and confirm toxic components.
• Examine emerging technologies prior to commercialization.
Accomplishments
• Evaluated health effects of inhaled nanoparticles from new and used diesel crankcase oil and sulfate.
• Discovered that oil and sulfate nanoparticles had little lung toxicity, but altered responses of immune cells elsewhere in the body.
• Completed analysis of results from a comprehensive study of the effects of repeated inhalation exposure to laboratory-generated gasoline emissions.
• Discovered that inhaled nitrogen oxide and carbon monoxide can duplicate some effects of gasoline emissions on blood vessels outside the lung.
Future Directions
• This subproject of the Health Impacts activity will be completed in early FY 2008.
• Wrap-up will include examining effects of nanoparticles and emission gases at lower concentrations, and publishing results.
• Future effort in this area will focus on evaluating emerging technologies.
This project is the biological evaluation subproject of the Health Impacts activity, and supports meeting DOE technical targets by: 1) placing in proper context the health hazards of engine emissions relative to other air quality hazards; 2) comparing the relative hazards of emissions from different fuel, engine, and emission reduction technologies; 3) determining the key toxic components among the hundreds of components of vehicle emissions; 4) demonstrating that reductions in emissions are paralleled by reductions in health hazards; and 5) evaluating emissions from emerging technologies to avoid unintended health consequences prior to commercialization. This project addresses potentially technology-limiting issues that are not addressed in other DOE or non-DOE programs. This project complements other Health Impacts subprojects that are characterizing emissions, determining the impacts of emissions on air quality, and conducting long-term health studies of 2007 2010-compliant diesel systems.
Approach
This project employs a four-tactic strategy to placing the health hazards of vehicle emissions in proper context, identifying the key toxic components, and evaluating new technologies. The first tactic involves laboratory evaluations of emission samples collected from vehicles and environments elsewhere. The second tactic involves animal studies of inhaled whole emissions, separated fractions of emissions, and specialized aerosols generated in the laboratory. Tissue oxidative stress, lung inflammation, cardiovascular effects, and immune responses are evaluated. The third tactic employs multivariate and univariate statistical analyses of data on composition vs. biological response
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to identify components that cause adverse effects. The fourth tactic involves working with DOE managers and industry partners to identify advanced technologies having the greatest near-term commercialization potential, and using the above approaches to evaluate those technologies for unintended health consequences.
Work during the past year focused primarily on two issues pertaining to current technologies in order to clarify issues that must be addressed for emerging technologies: 1) the health importance of emission nanoparticles; and 2) the health effects of gases that comprise the non-particulate components of gasoline and diesel engine emissions. There has been considerable speculation about the health effects of so-called "nanoparticles" (under 50 nm diameter) from combustion and other sources. Questions have been raised about the importance of nanoparticles formed by condensation of vapors downstream of exhaust aftertreatment devices. Such particles have always existed in engine emissions, but no technology has been available for separating them from other emissions for biological studies. A vaporization-condensation method was developed by this project last year to generate aerosols of nanoparticles from crankcase oil and sulfate, which are the primary sources of this material in contemporary emissions. This year, mice were exposed by inhalation to aerosols of new and used diesel engine lubrication oil and sulfate at a single high concentration to determine if measurable effects occur.
During the past few years, this project collaborated with other federal and non-federal partners (including several major large engine manufacturers and fuel providers) to conduct detailed studies directly comparing health effects of engine emissions to those of other pollution sources. Results finalized last year yielded the unexpected finding that blood vessels outside the lung were adversely affected by non-particulate components of gasoline emissions [3] . We hypothesized that nitrogen oxides and carbon monoxide might produce these effects through certain cellular chemical reactions, and might thus explain a portion of the known linkage between close proximity to traffic and cardiovascular effects in humans. This year, we exposed mice to these gases in pure form to determine whether these mechanisms were plausible.
results
The detailed results of this project are communicated in numerous technical presentations and peer-reviewed scientific publications (FY 2007 products listed in Publications/Presentations, full listing available on request). Key recent results are summarized here.
For an initial exploration of the plausibility of hazard from emission nanoparticles, mice were exposed 6 hours/day for 7 days to aerosols of 20 nm oil and sulfate nanoparticles at 10 6 particles/cubic centimeter. Aerosols were formed by heating oil or dilute sulfuric acid, followed by carefully controlled condensation and dilution. We used new Shell Rotella-T  15W-40 crankcase oil and the same oil from a normal change interval of a 2000 model Cummins 5.9L ISB engine using pre-2007 certification fuel and operated on repeated Environmental Protection Agency (EPA) heavy-duty certification cycles. Lung irritation was evaluated by analysis of lung surface fluid and histopathology. Earlier studies had revealed that the function of immune cells of the spleen was diminished by inhaled diesel emissions and wood smoke [1, 2] . Cells (T and B lymphocytes) were therefore removed from spleens of nanoparticle exposed mice and their ability to divide and produce antibody were measured.
The exposures to nanoparticles did not cause evidence of lung inflammation, either by histopathology or cell and biochemical markers in airway fluid. It is notable that exposure to this high concentration of the three aerosols did not cause inflammatory or irritant responses of the types considered sensitive indicators of the effects of whole emissions in human subjects. The only evidence that the lungs were exposed was an increase in tissue levels of hemeoxygenase-1, a general marker that is increased by many inhaled pollutants.
The exposure caused a mild suppression of the systemic (outside the lung) immune system. In a systemic immune response, lymphocytes in the spleen and other lymphoid tissues must divide to produce more cells, and must also produce antibodies to foreign materials. Two types of lymphocytes, T and B cells, were removed from the spleen and treated with materials that stimulate cell division and antibody production. In condensate-exposed animals, the cell division responses of both cell types were similarly reduced ( Figure 1 , showing only T cells). New and used oil caused similar modest reductions (approximately 20%), and sulfate caused a greater (nearly 40%) reduction. The three exposures also reduced the ability of cells to produce antibodies (Figure 2 , showing only T cells). New and used oil caused reduced antibody formation approximately 60%, but sulfate reduced antibody production by over 70%.
These initial findings provide important new information. First, nanoparticles may present little, if any, hazard to the lung, but may have effects on the systemic immune system. Second, there was no difference between the responses to new and used diesel crankcase oil, suggesting that contaminants accumulating normally in diesel crankcase oil may not present an increasing hazard as they accumulate. Third, pure sulfate nanoparticles having quite different chemistry than oil caused the same effects, and actually caused greater immune suppression than the oil aerosols. Together with the concurrent finding in hemeoxygenase-1 and matrix metalloproteinase-9. However, some other indicators of vascular response that were altered in the gasoline emission study were not altered by any of the single-gas exposures.
Although only a preliminary exploration, this study provided useful information. First, neither NO 2 nor CO at levels meeting current environmental standards caused measurable effects. The lack of effect of NO 2 is not surprising, because the reactivity of the gas would be expected to prevent any direct effect on tissues outside the lung. Second, the fact that high concentrations of both NO and CO did cause measurable effects suggests another project that solid carbon nanoparticles cause very similar effects [4] and the earlier finding that whole diesel emissions and wood smoke exert similar systemic immune effects [1, 2] , these results suggest a general response to nanoparticles and pollution mixtures rather than a specific response to engine emissions. It will be important to follow up these first results with exposures to lower concentrations of emissions nanoparticles, to determine whether more broadly-relevant exposures cause measurable effects.
In the second study, mice were exposed 6 hours/ day for 7 days to 17 ppm nitrogen oxide (NO), 0.2 or Advanced Combustion Engine Technologies that our hypotheses about the mechanisms of response to high levels of gasoline emissions are at least partially correct. Third, the fact that only some, but not all, of the markers of blood vessel effects were increased suggests that other non-particulate emissions, such as volatile organic compounds, also contributed to vascular responses at high concentrations of filtered gasoline emissions. Experimental logistics limited the number of exposures that could be included in this series; exposures to a lower concentration of NO and to a combination of NO and CO should be conducted. It will be important to determine whether more realistic exposures to NO present a hazard, and whether the effects of NO and CO are additive.
conclusions
Emissions from all internal combustion motive power technologies evaluated to date are attended by potential adverse health impacts of some nature and at some exposure level. These effects need to be considered in the evaluation of emerging technologies. The new evidence indicates that attention to crankcase oil emissions is warranted, and emissions of organic and sulfate condensate nanoparticles should be minimized. The evidence also suggests that the non-particle components of emissions warrant continued attention. Fortunately, with few exceptions, significant effects are only observed at the highest exposure concentrations that might be encountered, and such exposures in a few occupational settings or traffic "hotspots" should be of shorter duration than the experimental exposures. Also fortunately, the fuel-trap-catalyst technologies required to meet 2010 on-road diesel emission standards should markedly reduce not only gases, but also vapors that could condense to form nanoparticles.
FY 2007 is the last year of funding for this project in its present form. Many, but not all, issues pertaining to the purpose of this project have been addressed. As noted above, a few additional exposures would be required to complete the recent work by determining whether effects occur at more widespread exposure levels. This will be accomplished as funding is available. One engine/aftertreatment system will be selected for health testing.
references
II.D.4 The Advanced Collaborative Emissions Study (ACES)
• Phase 2: Extensive emissions characterization of a group of production-intent engine and control systems meeting the 2010 standards (including more advanced NOx controls to meet the more stringent 2010 NOx standards).
• Phase 3: One selected 2007-compliant engine will be installed in a specially-designed emissions generation and animal exposure facility (Phase 3A) and used in chronic and shorter-term health effects studies to form the basis of the ACES safety assessment (Phases 3B and 3C). This will include periodic emissions characterization during both a core 24-month chronic bioassay of cancer endpoints in rats and shorter term biological screening assays in both rats and mice (Phase 3B) as well as emission characterization during a set of shorter animal exposures and biological screening using accepted toxicological tests after the end of the chronic bioassay (Phase 3C). (NOTE: Only the emissions characterization and shorter-term biological screening activities at the beginning and during Phase 3 are components of the DOE ACES contract.)
Accomplishments
General Oversight
• Held meetings with the ACES Oversight, Advisory and Steering Committees regarding finalization of emissions generation and characterization, health effects assessment, and cost savings options for Phase 3, and to finalize financial commitments (Fall 2006).
• Held a meeting with the ACES Oversight and Advisory Committees to discuss progress and technical issues (April 2007).
• • Finalized the contract with SwRI for Phase 1 emissions characterization (December 2006).
• Completed preparation of the engine testing facility at SwRI (February 2007).
• Received four test engines from the participating engine manufacturers at SwRI and agreed upon the order in which they would be tested (April 2007).
• 
Phase 3
• Selected LRRI to conduct Phase 3A and B, the core emissions characterization and chronic bioassay (Fall 2006).
• Finalized details of facility development, emissions characterization, and health effects assessment for Phase 3 with the LRRI principal investigator and the ACES HEI Oversight Committee, specifically regarding cost savings options (Fall 2006).
• Conducted a site visit to LRRI to discuss cost-saving options related to engine facility, dynamometer, and dilution systems with key experts on the HEI ACES Oversight and Advisory Committees and additional experts identified by CRC (December 2006).
• Extended the deadline for submission of proposals for biological screening under RFA 06-2 to May 24, 2007 to increase the potential of a large number of high quality applications for additional biological screening during Phase 3 and encouraged prospective applicants to contact the LRRI team to discuss technical and logistical issues (Spring 2007).
• Finalized remaining technical details of the chronic exposure bioassay and related biological screening studies in Phase 3 (May 2007).
• Agreed upon a revised budget with LRRI, completed the first round of contract negotiations, and began facility implementation (August 2007).
• Received five applications for shorter term biological screening studies during Phase 3B submitted under RFA 06-2 (May and June 2007).
• Reviewed the five applications to RFA 06-2 with an expert Review Panel and solicited revised applications (August 2007).
• Discussed with the four engine manufacturers and CRC the specifications of the facility implementation at LRRI in order to allow any of the 2007-compliant engines to be accommodated, if selected (August, September 2007). • Finalize the engine selection criteria described in the Initial Plan for Engine Selection with the ACES Oversight and Steering Committees (Fall 2007).
Future Directions
• Continue to work with LRRI, CRC, and the engine manufacturers to determine appropriate specifications for the LRRI engine facility (Fall 2007).
• Receive detailed the emissions characterization data for all four engines from SwRI and collaborating researchers at Desert Research Institute (Winter 2007).
• Adjust the engine selection criteria if warranted by the findings, as described in the Final Draft Initial Plan; agree upon a Final Plan for Engine Selection (Fall 2007).
• Select one engine for use in Phase 3; receive a duplicate engine and characterize its emissions at SwRI (Spring 2008).
• Ship the selected engine and its duplicate to LRRI for installation in their facility (Spring 2008).
• Receive a Phase 1 Final Report from SwRI (Summer 2008).
Phase 3
• Finalize the second stage of contract negotiations for conduct of the chronic bioassay and biological screening at LRRI (Winter 2007).
• Select contractors to conduct the biological screening study for Phase 3B (Fall 2007).
• Finalize protocols for biological screening with those contractors and the investigators' team at LRRI (Winter/Spring 2008).
• Complete facility implementation at LRRI (Spring 2008).
• Install the selected engine and store the duplicate engine (Spring/Summer 2008).
• Perform initial emissions characterization of the selected and duplicate engines at LRRI to ensure both engines perform in a similar fashion as when they were characterized at SwRI (Summer 2008).
• Start animal exposures for the chronic bioassay and biological screening studies (Fall 2008) .
ACES is a cooperative, multi-party effort to characterize the emissions and assess the safety of advanced heavy-heavy duty diesel engine and aftertreatment systems and fuels designed to meet the 2007 and 2010 emissions standards for PM and NOx. The ACES program is being carried out by HEI and CRC. It is utilizing established emissions Advanced Combustion Engine Technologies characterization and toxicological test methods to assess the possible health effects of production-intent engine and control technology combinations that will be introduced into the market during the 2007-2010 time period. This is in direct response to calls in the U.S. Environmental Protection Agency Health Assessment Document for Diesel Engine Exhaust [1] for assessment and reconsideration of diesel emissions and health risk with the advent of new cleaner technologies.
The characterization of emissions from representative, production-intent advanced compression ignition (CI) engine systems will include comprehensive analyses of the gaseous and particulate material, especially those species that have been identified as having potential health significance. The core toxicological study will include detailed emissions characterization at its inception, and periodically throughout a two-year chronic inhalation bioassay in rats similar to the standard National Toxicology Program (NTP) bioassay. Other specific biological screening studies also will be undertaken in both rats and mice, to evaluate these engine systems with respect to carefully selected respiratory, immunologic, and genotoxic effects for which there are accepted toxicologic tests. It is anticipated that these emissions characterization and health effects studies will assess the safety of these advanced CI engine systems, will identify and assess any unforeseen changes in the emissions as a result of the technology changes, and will contribute to the development of a database to inform future assessments of these advanced engine and control systems.
Approach
Experimental work under ACES will be performed in three phases, as outlined in the Objectives. Detailed emissions characterization (Phases 1 and 2) will be performed by an existing engine laboratory (SwRI) that meets the U.S. Environmental Protection Agency specifications for 2007 and 2010 engine testing. In Phase 1, emissions from four 2007-compliant engine/ control systems will be characterized. One engine will be selected for health testing in Phase 3. In Phase 2, emissions from four 2010-compliant engine/control systems will be characterized. In Phase 3, one selected 2007-compliant engine/control system will be installed in a specially designed emission generation facility connected to a health testing facility at LRRI to conduct a chronic inhalation bioassay in rats and shorter term biological screening in rats and mice. During the 2-year bioassay, emissions will be characterized at regular intervals throughout the testing.
The emissions characterization work will be overseen by CRC and its ACES Panel. The health effects assessment will be overseen by HEI and its ACES Oversight Committee. Set-up of the emission generation facility at the health effects testing facility (for Phase 3) and finalizing the protocols for periodic emission characterization throughout Phase 3 will be done with input from the team of investigators selected to conduct emissions characterization in Phase 1 and CRC.
results
The emissions characterization in Phase 1 is well underway; at this time characterization of two of the four engine/aftertreatment combinations has been completed. Successful meetings were conducted with multiple stakeholders of ACES to discuss and agree upon technical issues for both Phases 1 and 3. Much progress was made this year in terms of developing and finalizing the test cycles and other technical procedures, including how to handle trap regeneration and crankcase emissions. Initial contract negotiations with the emissions characterization and health testing facility for conduct of Phase 3 were completed; facility implementation was started after various cost saving options were identified and agreed upon. A final draft of the Initial Plan for Engine Selection has been written and circulated and is expected to be finalized soon.
conclusions
We have made substantial progress towards the implementation of the project: (1) emissions characterization in Phase 1 is well underway, and (2) facility implementation for Phase 3 has started and detailed experimental protocols will be finalized in the coming months. Furthermore, five additional teams of investigators have submitted proposals for supplementary biological screening studies to address important health endpoints; revised proposals will be reviewed and funding decisions made in the Fall of 2007. 
